FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							, .				1								
1. Name and Address of Reporting Person* <u>Horn Margaret A</u>				<u>S</u>	2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC SGMO								(Che	elationship of ck all appliced Director	cable)	g Pers	son(s) to Iss 10% Ov		
(Last)	,	irst) HERAPEUTICS	(Middle)		3. 1	3. Date of Earliest Transaction (Month/Day/Year) 06/04/2024										Officer (give title below)		Other (s below)	pecify
501 CANAL BLVD.					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	OND C	A	94084													led by Mor		orting Person	
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to													
									defense cor							n or written	plan th	at is intended	to
		Tab	ole I - Nor	n-Deri	vativ	e Se	curities	s Ac	quired, l	Disp	osed o	f, or Be	enef	icially	/ Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		Transaction Disposed Code (Instr. 5)			rities Acquired (A) or ed Of (D) (Instr. 3, 4 a				es Foilowing (I)		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 06/04/				04/202	./2024		A		25,000	0 ⁽¹⁾ A \$0		\$ <mark>0</mark>	57,650 ⁽²⁾			D			
		-	Table II -						uired, Di						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transaction (Instr. 4)	Ow Fo ly Dir or (l)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	or Nu of	nount mber ares					
Stock Option (Right to Buy)	\$0.5676	06/04/2024			Α		50,000		(3)	0	6/03/2034	Common Stock	50	,000	\$0	50,00	0	D	

Explanation of Responses:

- 1. Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
- 2. Includes 12,500 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in two equal annual installments of 6,250 shares on each of December 15, 2024 and 2025.
- 3. The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

/s/ Ron A. Metzger, Attorneyin-Fact

06/06/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.